What is ZYPPAH?
ZYPPAH operates at the intersection of medical device innovation and consumer wellness, specializing in proprietary anti-snoring solutions. The company is best known for its FDA-cleared mouthpiece, which utilizes a patented tongue-stabilization mechanism to address the root causes of snoring. With a clinical efficacy rate of 91% and a customer base exceeding 500,000 individuals, ZYPPAH has successfully transitioned from a niche startup to a recognized authority in sleep hygiene. Their product ecosystem, which includes complementary items like mouth tape, is fully FSA/HSA approved, facilitating broader accessibility for consumers seeking to improve their sleep quality and overall health outcomes.
The company's business model is anchored in high-conversion direct-to-consumer channels, supported by a strong value proposition that includes a 91-day money-back guarantee. This focus on consumer trust and clinical validation has allowed ZYPPAH to maintain a significant competitive advantage in the crowded sleep-aid market.
How much funding has ZYPPAH raised?
ZYPPAH has raised a total of $144K across 1 funding round:
Debt
$144K
Debt (2021): $144K with participation from PPP
Key Investors in ZYPPAH
PPP
Public-Private Partnership
What's next for ZYPPAH?
With the recent infusion of capital, ZYPPAH is expected to scale its operational infrastructure and expand its reach into new demographic segments. The strategic focus will likely shift toward enhancing supply chain efficiencies and potentially diversifying its product portfolio to address broader sleep-related disorders. As the company moves into this next phase of growth, the emphasis will remain on maintaining clinical standards while scaling marketing efforts to capture a larger share of the global sleep wellness market. Investors are closely monitoring how this late-stage backing will translate into sustained revenue growth and long-term brand equity in the evolving health-tech landscape.
See full ZYPPAH company page
